Key result
Immune checkpoint inhibitors are associated with uncommon but potentially fatal cardiovascular toxicities, including myocarditis and arrhythmias, which carry high mortality despite glucocorticoids.
Why the study?
Immune checkpoint inhibitors provide mortality benefits in cancer but carry uncommon, potentially fatal cardiovascular toxicities with high mortality even under glucocorticoid treatment.
What are the cardiovascular toxicities associated with immune checkpoint inhibitors in cancer patients?
Design
Review
Authors
Loading...
May warrant increased surveillance for immune checkpoint inhibitor cardiotoxicity; leaves open prospective validation of management strategies.
What are the cardiovascular toxicities associated with immune checkpoint inhibitors in cancer patients?
Immune checkpoint inhibitors can cause uncommon but potentially fatal cardiovascular toxicities, requiring specific strategies for surveillance, diagnosis, and management.
Chen et al. (2019) conducted a review in Cancer. Immune checkpoint inhibitors was evaluated. Immune checkpoint inhibitors are associated with uncommon but potentially fatal cardiovascular toxicities, including myocarditis and arrhythmias, which carry high mortality despite glucocorticoids.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: